Market Data
Market Cap₹282.55 Cr.
52W High₹104.1
Current Price₹99.65
52W Low₹50.4
Down from 52W High4.3 %
Face Value₹10
Performance
ROCE4.91 %
ROE2.77 %
EPS (TTM)₹0.36
EPS Prev Qtr₹0.55
EPS Last Year₹0.36
EBITDA Qtr₹0.48 Cr.
Book Value₹53
Financial Health
Debt/Equity0.33
Debt/Profit11.98
Total Assets₹297.25 Cr.
Promoter Holding37.71 %
Earning Power1.2 %
Valuation
Stock P/E67.79
Industry P/E33.3
Price to Book1.88
Price to Sales0.68
Graham Number₹41.87
Key Metrics
__derived
1
Face Value
₹10
About Aarey Drugs & Pharmaceuticals Ltd
Healthcare · Pharmaceuticals
Aarey Drugs & Pharmaceuticals Ltd is listed on NSE in the Healthcare / Pharmaceuticals sector. Face value ₹10. Market cap ₹282.55 Cr.
Price Chart
Strengths & Weaknesses
Strengths
- The company maintains a moderate debt-to-equity ratio of 0.26, indicating a relatively conservative capital structure.
- The promoter holding stands at 37.71%, suggesting a significant level of insider control and alignment of interests.
Weaknesses
- The company exhibits a high P/E ratio of 68.62, which may indicate that the stock is overvalued relative to its earnings.
- The P/B ratio of 2.14 suggests that the market values the company at a premium compared to its book value.
- The ROCE of 5.84% and ROE of 3.12% are relatively low, indicating inefficient use of capital and potential challenges in generating returns.
- With a net profit of ₹4.17 Cr on a revenue of ₹414.69 Cr, the company shows a very low profit margin, raising concerns about profitability and operational efficiency.
Peer Comparison
| Name | CMP | P/E | Market Cap | Div Yield | NP Qtr | Qtr Profit Var% | Sales Qtr | Qtr Sales Var% | ROCE% | Debt/Eq |
|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | - | 36.9 | ₹4,46,276.3 Cr | 0.86% | ₹12,172.7 Cr | - | ₹59,910.52 Cr | - | 18.72% | 0.05 |
| Divis Laboratories Ltd | - | 85.97 | ₹2,51,531.48 Cr | 0.32% | ₹2,925 Cr | - | ₹11,230 Cr | - | 23.04% | 0 |
| Torrent Pharmaceuticals Ltd | - | 78.4 | ₹1,86,956.51 Cr | 0.77% | ₹2,156 Cr | - | ₹15,723 Cr | - | 15.1% | 1.76 |
| Zydus Lifesciences Ltd | - | 26.64 | ₹1,19,221.66 Cr | 0.08% | ₹4,492.2 Cr | - | ₹28,591.7 Cr | - | 16.76% | 0.43 |
| Cipla Ltd | - | 33.13 | ₹1,11,725.01 Cr | 0.94% | ₹3,364.84 Cr | - | ₹28,324.4 Cr | - | 13.24% | 0.01 |
| Laurus Labs Ltd | - | 98.01 | ₹1,07,271.96 Cr | 0.06% | ₹1,090.76 Cr | - | ₹7,269.64 Cr | - | 20.79% | 0.45 |
| Mankind Pharma Ltd | - | 51.42 | ₹1,05,107.48 Cr | 0.04% | ₹2,067.57 Cr | - | ₹14,737.88 Cr | - | 13.95% | 0.38 |
| Dr Reddys Laboratories Ltd | - | 32.31 | ₹1,04,334.48 Cr | 0.64% | ₹3,183.3 Cr | - | ₹33,227.9 Cr | - | 10.05% | 0.17 |
| Aurobindo Pharma Ltd | - | 26.61 | ₹97,986.86 Cr | 0.23% | ₹3,710.8 Cr | - | ₹34,935.29 Cr | - | 12.75% | 0.2 |
| Lupin Ltd | - | 16.63 | ₹94,189.9 Cr | 0.87% | ₹5,550.99 Cr | - | ₹29,966.58 Cr | - | 27.95% | 0.26 |
| Glenmark Pharmaceuticals Ltd | - | 37.59 | ₹67,587.09 Cr | 0.1% | ₹1,797.81 Cr | - | ₹17,736.56 Cr | - | 24.78% | 0.25 |
| Alkem Laboratories Ltd | - | 29.02 | ₹62,609.02 Cr | 1.01% | ₹2,206.3 Cr | - | ₹15,081.28 Cr | - | 19.75% | 0.12 |
| Biocon Ltd | - | 111.18 | ₹61,602.44 Cr | 0.13% | ₹416.4 Cr | - | ₹17,321.1 Cr | - | 2.87% | 0.43 |
| Abbott India Ltd | - | 35.88 | ₹57,939.73 Cr | 1.74% | ₹1,614.68 Cr | - | ₹7,004.38 Cr | - | 45.73% | 0 |
| Gland Pharma Ltd | - | 43.62 | ₹49,299.85 Cr | 0.67% | ₹1,128.8 Cr | - | ₹6,725.3 Cr | - | 15.21% | 0.02 |
| Ipca Laboratories Ltd | - | 36.55 | ₹49,280.78 Cr | 0.31% | ₹1,379.76 Cr | - | ₹10,125.58 Cr | - | 21.48% | 0.09 |
| Anthem Biosciences Ltd | - | 85 | ₹49,084.9 Cr | 0.23% | ₹575.95 Cr | - | ₹2,002.34 Cr | - | 25.5% | 0.02 |
| Glaxosmithkline Pharmaceuticals Ltd | - | 44.95 | ₹47,217.7 Cr | 2.05% | ₹1,068.15 Cr | - | ₹3,954.94 Cr | - | 64.07% | 0 |
| Ajanta Pharma Ltd | - | 39.17 | ₹44,452.1 Cr | 0.79% | ₹1,134.88 Cr | - | ₹5,776.17 Cr | - | 31.81% | 0.05 |
| J B Chemicals & Pharmaceuticals Ltd | - | 53.3 | ₹38,730.77 Cr | 0.39% | ₹709.46 Cr | - | ₹4,147.79 Cr | - | 23.03% | 0 |
Quarterly Results
📊 Jun 2026: Revenue fell 56.3% YoY, Profit fell 26.1% YoY
| Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 102.21 | 84.16 | 96.43 | 189.47 | 44.63 |
| ↳ QoQ Growth | - | -17.7% | +14.6% | +96.5% | -76.4% |
| Expenses | 101 | 82.21 | 98.77 | 185.98 | 44.15 |
| Operating Profit | 1.21 | 1.95 | -2.34 | 3.49 | 0.48 |
| OPM % | 1.18% | 2.32% | -2.43% | 1.84% | 1.08% |
| Other Income | 1.55 | 0.79 | 4.18 | -0.43 | 1.72 |
| Interest | 1.04 | 1.26 | 0.92 | 1.78 | 1.67 |
| Depreciation | 0.49 | 0.69 | 0.83 | 0.85 | 0.85 |
| EBITDA | 1.7 | 2.64 | -1.51 | 4.34 | 1.33 |
| EBITDA Margin % | 1.66% | 3.14% | -1.57% | 2.29% | 2.98% |
| Profit Before Tax | 1.73 | 1.48 | 0.92 | 1.28 | 0.52 |
| Tax % | 20.81% | 31.08% | 38.04% | -21.88% | -98.08% |
| Net Profit | 1.38 | 1.02 | 0.57 | 1.56 | 1.02 |
| ↳ QoQ Growth | - | -26.1% | -44.1% | +173.7% | -34.6% |
| EPS | 0.48 | 0.36 | 0.2 | 0.55 | 0.36 |
Profit & Loss
| Mar 2026 | TTM | |
|---|---|---|
| Sales | 472.27 | 414.69 |
| Expenses | 467.96 | 411.11 |
| Operating Profit | 4.31 | 3.58 |
| OPM % | 0.91% | 0.86% |
| Other Income | 6.09 | 6.26 |
| Interest | 5 | 5.63 |
| Depreciation | 2.86 | 3.22 |
| Profit Before Tax | 5.41 | 4.2 |
| Tax % | 16.45% | 0.48% |
| Net Profit | 4.53 | 4.17 |
| EPS | 1.59 | 1.47 |
Compounded Sales Growth
10Y
-
5Y
-
3Y
-
TTM
-
Compounded Profit Growth
10Y
-
5Y
-
3Y
-
TTM
-
Stock Price CAGR
10Y
-
5Y
-
3Y
-
1Y
26.48%
Return on Equity
10Y
-
5Y
-
3Y
-
Last Year
3.12%
Balance Sheet
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Equity Capital | 28.4543 | 28.45 |
| Reserves | 104.9962 | 121.97 |
| Borrowings | 34.86 | 49.96 |
| Other Liabilities | 122.28 | 96.87 |
| Total Liabilities | 290.592 | 297.25 |
| Fixed Assets | 16.2206 | 25.78 |
| CWIP | 0 | 0 |
| Investments | 2.12 | 2.12 |
| Other Assets | 272.25 | 269.35 |
| Total Assets | 290.592 | 297.25 |
Cash Flows
| Mar 2025 | |
|---|---|
| Cash from Operating Activity | 10.3004 |
| Cash from Investing Activity | -5.9394 |
| Cash from Financing Activity | -4.4821 |
| Net Cash Flow | -0.1211 |
Ratios
| Mar 2026 | |
|---|---|
| Debtor Days | - |
| Inventory Days | - |
| Days Payable | - |
| Cash Conversion Cycle | - |
| Working Capital Days | 191.12 |
| ROCE % | 1.74% |
Shareholding Pattern
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Promoters % | 44.8% | 39.06% | 37.71% | 37.71% |
| FIIs % | 1.13% | 3.86% | 4.18% | 4.8% |
| DIIs % | 0% | 0% | 1.62% | 1.62% |
| Public % | 47.01% | 45.4% | 43.71% | 41.66% |
| No. of Shareholders | 14,897 | 14,063 | 14,188 | 13,478 |
Major Shareholders (>1%)
- Bina Rajesh GhataliaPromoter and Promoter Group14.12%
- Mihir Rajesh GhataliaPromoter and Promoter Group10.00%
- Nimit ImpexPromoter and Promoter Group7.09%
- Nimit Rajesh GhataliaPromoter and Promoter Group4.06%
As of 2026-06-30View all shareholders →